Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Not listed Phase 2 Interventional

Study in Subjects With Moderate Atopic Dermatitis

ClinicalTrials.gov ID: NCT03859986

Public ClinicalTrials.gov record NCT03859986. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 25, 2026, 11:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study To Evaluate The Safety And Efficacy Of ALX-101 Topical Gel Administered Twice Daily In Adult And Adolescent Subjects With Moderate Atopic Dermatitis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase 2, randomized, double-blind, vehicle-controlled, parallel-group study to evaluate the safety and efficacy of ALX-101 Gel 5% and a matching ALX-101 Gel Vehicle when applied topically twice daily for 56 days in adult and adolescent subjects with moderate atopic dermatitis

Study identification

NCT ID
NCT03859986
Recruitment status
Not listed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Ralexar Therapeutics, Inc.
Industry
Enrollment
124 participants

Conditions and interventions

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 7, 2019
Primary completion
Dec 31, 2019
Completion
Dec 31, 2019
Last update posted
Nov 4, 2019

2019 – 2020

United States locations

U.S. sites
20
U.S. states
13
U.S. cities
20
Facility City State ZIP Site status
Ralexar Investigational Site 10 Beverly Hills California 90212 —
Ralexar Investigational Site 5 Los Angeles California 90045 —
Ralexar Investigational Site 3 Aventura Florida 33180 —
Ralexar Investigational Site 2 Jacksonville Florida 32256 —
Ralexar Investigational Site 22 Miami Florida 33147 —
Ralexar Investigational Site 18 Pinellas Park Florida 33781 —
Ralexar Investigational Site 6 Sanford Florida 32771 —
Ralexar Investigational Site 13 Marietta Georgia 30060 —
Ralexar Investigational Site 7 Boise Idaho 83713 —
Ralexar Investigational Site 21 Gurnee Illinois 60031 —
Ralexar Investigational Site 1 Indianapolis Indiana 46250 —
Ralexar Investigational Site 17 Louisville Kentucky 40202 —
Ralexar Investigational Site 12 Las Vegas Nevada 89177 —
Ralexar Investigational Site 14 Beachwood Ohio 44122 —
Ralexar Investigational Site 8 Fairborn Ohio 45324 —
Ralexar Investigational Site 9 Oklahoma City Oklahoma 73118 —
Ralexar Investigational Site 19 Spartanburg South Carolina 29307 —
Ralexar Investigational Site 16 Austin Texas 78745 —
Ralexar Investigational Site 4 San Antonio Texas 78213 —
Ralexar Investigational Site 15 Seattle Washington 98101 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03859986, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 4, 2019 · Synced Sep 25, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03859986 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →